Clinical trials for Amyloidosis

24 currently recruiting clinical trials

Phase 3 Amyloidosis #NCT07207811 #2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3 Amyloidosis #NCT06128629 #2023-507220-23-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
5 recruiting sites
Intellia Therapeutics
Phase 3 Amyloidosis #NCT06563895 #2024-513547-82-00
Required histologic types
Other
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required organ involvement status
Absence
5 recruiting sites
Eidos Therapeutics, a BridgeBio company
Phase 3 Amyloidosis #NCT07052903 #2024-519917-72-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3 Amyloidosis #NCT07223203 #2025-522544-40-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Neurological
3 recruiting sites
Alnylam Pharmaceuticals
Phase 2 Amyloidosis #NCT06649695 #2024-519191-90-00
Required histologic types
AL Amyloidosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies Proteasome inhibitor
Required Mayo Clinic stages
Stade I Stade II Stade IIIA
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
European Myeloma Network B.V.
Phase 1 / Phase 2 Amyloidosis #NCT06158854
Required histologic types
AL Amyloidosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Monoclonal antibodies Proteasome inhibitor
Required organ involvement status
Presence
Required Mayo Clinic stages
Stade I Stade II Stade IIIA
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Abbvie
Phase 1 Amyloidosis #NCT05652335 #2022-001465-12
Required histologic types
AL Amyloidosis
Required number of previous lines of therapy
1 2 3 or more
Required organ involvement status
Presence
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Janssen